Literature DB >> 23374281

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Vishnu C Ramani1, Anurag Purushothaman, Mark D Stewart, Camilla A Thompson, Israel Vlodavsky, Jessie L-S Au, Ralph D Sanderson.   

Abstract

Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up-regulation of growth factor expression and increased shedding of syndecan-1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan-1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan-1 axis hold promise for blocking the aggressive behaviour of cancer.
© 2013 The Authors Journal compilation © 2013 FEBS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23374281      PMCID: PMC3651779          DOI: 10.1111/febs.12168

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  113 in total

Review 1.  Shedding; towards a new paradigm of syndecan function in cancer.

Authors:  Sojoong Choi; Hawon Lee; Jung Ran Choi; Eok Soo Oh
Journal:  BMB Rep       Date:  2010-05       Impact factor: 4.778

2.  Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products.

Authors:  S Tumova; B A Hatch; D J Law; K J Bame
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

3.  Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements.

Authors:  Ulrika Brockstedt; Katalin Dobra; Mervi Nurminen; Anders Hjerpe
Journal:  Exp Cell Res       Date:  2002-04-01       Impact factor: 3.905

4.  Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.

Authors:  O Hjertner; M L Torgersen; C Seidel; H Hjorth-Hansen; A Waage; M Børset; A Sundan
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

5.  Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.

Authors:  Vishnu C Ramani; Pamela S Pruett; Camilla A Thompson; Lawrence D DeLucas; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

6.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

Review 7.  Heparanase: one molecule with multiple functions in cancer progression.

Authors:  Israel Vlodavsky; Michael Elkin; Ghada Abboud-Jarrous; Flonia Levi-Adam; Liat Fuks; Itay Shafat; Neta Ilan
Journal:  Connect Tissue Res       Date:  2008       Impact factor: 3.417

8.  Biosynthesis of heparan sulfate on beta-D-xylosides depends on aglycone structure.

Authors:  T A Fritz; F N Lugemwa; A K Sarkar; J D Esko
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

9.  Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation.

Authors:  Gui Su; Stacy A Blaine; Dianhua Qiao; Andreas Friedl
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  77 in total

Review 1.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  The potential of heparanase as a therapeutic target in cancer.

Authors:  Claudio Pisano; Israel Vlodavsky; Neta Ilan; Franco Zunino
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

Review 3.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

4.  Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Authors:  Vishnu C Ramani; Israel Vlodavsky; Mary Ng; Yi Zhang; Paola Barbieri; Alessandro Noseda; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2016-03-22       Impact factor: 11.583

Review 5.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

6.  Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.

Authors:  Peter L Voyvodic; Daniel Min; Robert Liu; Evan Williams; Vipul Chitalia; Andrew K Dunn; Aaron B Baker
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 7.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

8.  Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.

Authors:  Zurab Surviladze; Rosa T Sterkand; Michelle A Ozbun
Journal:  J Gen Virol       Date:  2015-08       Impact factor: 3.891

9.  PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

Authors:  Boris Winterhoff; Luisa Freyer; Edward Hammond; Shailendra Giri; Susmita Mondal; Debarshi Roy; Attila Teoman; Sally A Mullany; Robert Hoffmann; Antonia von Bismarck; Jeremy Chien; Matthew S Block; Michael Millward; Darryn Bampton; Keith Dredge; Viji Shridhar
Journal:  Eur J Cancer       Date:  2015-03-05       Impact factor: 9.162

Review 10.  Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering.

Authors:  Matthew Suflita; Li Fu; Wenqin He; Mattheos Koffas; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2015-07-29       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.